NCT01455532View on ClinicalTrials.gov

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

April 30, 2014

Conditions
Neoplasm Malignant
Interventions
DRUG

Iniparib (SAR240550-BSI-201)

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

DRUG

Gemcitabine

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

DRUG

Carboplatin

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

DRUG

Placlitaxel

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

DRUG

Pegylated liposomal doxorubicin

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

Trial Locations (6)

30912

Investigational Site Number 840010, Augusta

63110

Investigational Site Number 840007, St Louis

78229

Investigational Site Number 840006, San Antonio

85258

Investigational Site Number 840002, Scottsdale

90048

Investigational Site Number 840004, Los Angeles

45267-0542

Investigational Site Number 840001, Cincinnati

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01455532 - A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | Biotech Hunter | Biotech Hunter